Previous 10 | Next 10 |
Shares of DermTech (NASDAQ:DMTK) are down 14% in after-hours trading after its Q3 2021 results missed on both EPS and revenue and it revised its full-year revenue outlook. The company now estimates full-year assay revenue of $10.5M-$12M. Consensus is $13.3M. Almost all of DermT...
DermTech (NASDAQ:DMTK): Q3 GAAP EPS of -$0.68 misses by $0.04. Revenue of $3M (+120.6% Y/Y) misses by $0.42M. Shares -16%. Press Release Due to unforeseen impacts from the Delta variant and hurricane Ida, Management revised its estimated full year 2021 assay revenue to be between $10.5 millio...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported unaudited financial results for the quarter ended September 30, 2021. Third Quarter 2021 Highlights Billable sample ...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, and DermatologistOnCall , a leading dermatology telehealth provider in the U.S., announced today an agree...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today it plans to release its third quarter 2021 financial results after the market closes on Tuesday, November 9, 2021. In conjunction...
DermTech (NASDAQ: DMTK) , a company that is trying to redefine testing for skin cancer, has been a sleeper stock for the better half of 2021. The company has created a patch that makes testing for skin cancer easier and more accurate, yet the stock has fallen 60% from its February h...
DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the Company’s participation in the inaugural Alliance for Innovation in Integrated Health...
Alexandria Real Estate Equities and Kilroy Realty have each made attractive moves to expand their life science portfolios. Recent transactions in the net lease sector by Four Corners Property Trust, CTO Realty, and Realty Income reflect stable cap rates. Gateway office appears to ...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the appointment of Nathalie Gerschtein Keraudy, President of the Consumer Products Division of L’Oréal, to its b...
DermTech , Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today the sponsorship of the San Diego Open , an ATP 250 tournament, and a partnership with San...